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Background: Experimental studies have shown that high free fatty acid (FFA) and low adiponectin (ADIPO) levels
are involved in the mechanisms by which adiposity promotes insulin resistance (IR). However, no previous clinical
studies have simultaneously analysed the relative contribution of FFA and ADIPO levels on the relation of
abdominal visceral fat (AVF) with insulin resistance.
Objective: To analyse the contribution of low ADIPO (adiponectin < =p25th: 8.67 μg/mL in women and 5.30 μg/mL
in men), and high FFAs (FFAs > =p75th: 0.745 mEq/L in women and 0.60 mEq/L in men) to the association of high
AVF (AVF > =p75th: 127 cm2 in women; 152.7 cm2 in men) with insulin resistance (HOMA-IR > =75th: 3.58 in
women and 3.12 in men), in non-diabetic subjects.
Material and methods: A cross-sectional analysis was performed including 1217 control participants of the Genetics
of Atherosclerotic Disease study (GEA). Clinical, tomographic and biochemical parameters were measured in all
participants. Logistic regression models were used to assess the association of high AVF with IR stratifying according to
gender, and to normal or low ADIPO and normal or high FFA serum levels.
Results: In comparison to referent group, in men low ADIPO unlike high FFA increased the risk of IR. Females with
normal AVF and low ADIPO, or high AVF and normal ADIPO had aprox 3 folds risk of IR (OR [IC95%]: 3.7 [2.1-6.6],
p < 0.001, and 3.4 [2.0-5.7], p < 0.001; respectively). The risk increased to 7.6 [4.2-13.8], p < 0.001 when high AVF
and low ADIPO were present. Irrespective of AVF, the effect of low ADIPO on IR was higher than that seen for
high FFA. Besides, our results suggest an additive effect of high AVF, high FFA and low ADIPO on the IR prevalence.
Conclusions: The present study provides novel and important information about the combined effect of high AVF
and low ADIPO on the risk of IR. Furthermore, our data suggest that the effect of low adiponectin levels on the high
AVF-IR association is stronger than that observed for high FFA, suggesting that adiponectin could be used as biomarker
to identify subjects at high risk for T2DM and CAD.
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Coronary artery disease (CAD) and type 2 diabetes mel-
litus (T2DM) are currently leading causes of mortality
worldwide [1]. Although obesity has been recognized as
one of the most important risk factors for both these
chronic diseases [2], approximately 30% of overweight or
obese subjects [body mass index (BMI) ≥ 25 Kg/m2], do
not show metabolic abnormalities [3,4]. Several studies
have sought to identify when obesity is associated with
metabolic abnormalities and increased risk of developing
T2DM and CAD [5,6]. Abdominal visceral fat (AVF) has
proven to be a better predictor of metabolic abnormal-
ities (particularly insulin resistance) than BMI and waist
circumference [7].
Experimental evidence suggests that high free fatty
acid (FFA) [8] and low adiponectin (ADIPO) plasma
levels [9] play a key role in the mechanisms by which ex-
cess of adiposity promotes insulin resistance [10,11].
Nevertheless, few clinical investigations have analysed
the effect of high FFA serum levels on the association
between increased AVF and insulin resistance (IR) [12].
As far as we know, no previous epidemiological studies
have analysed the contribution of ADIPO serum levels
on AVF-IR association. Considering that insulin resist-
ance is a crucial feature of the metabolic abnormalities
observed in obese subjects, the purpose of the present
study was to analyse the role of ADIPO and FFA levels
on the association between high AVF and IR in a
Mexican-Mestizo population.
Our data suggest that the effect of low adiponectin
levels on the high AVF-IR association is stronger than
that observed for high FFA, suggesting that adiponectin
could be used as biomarker to identify subjects at high
risk for T2DM and CAD.
Material and methods
Study subjects
The study population was recruited from controls par-
ticipating in the Genetics of Atherosclerotic Disease
(GEA) study. The GEA study was designed to examine
the genomic bases of CAD and to assess traditional and
emerging risk factors for clinical and subclinical athero-
sclerotic vascular disease in the adult Mexican popula-
tion [13]. All GEA participants are of self-reported
Mexican-Mestizo ancestry (Spaniards and Native-American
Indians). Briefly, a convenience sample of 1200 CAD
patients and 1500 control subjects aged 30 to 75 years
was recruited from residents in Mexico City. Patients
with established premature CAD were selected from
the outpatient clinic of the National Institute of Cardi-
ology. Volunteer control participants with a negative
family history of premature CAD and no personal his-
tory of cardiovascular disease were recruited from ap-
parently healthy blood donors and through brochuresposted in social service centers. Coronary patients and
control subjects with history of renal, liver, thyroid or
malignant disease, and corticosteroid use were not in-
cluded. The GEA study was approved by the Institu-
tional Review Board of the National Institute of
Cardiology and conducted according to the Declaration
of Helsinki. Written informed consent was obtained
from participants.
For the purpose of the present study, we included only
control subjects without T2DM. All participants an-
swered several structured questionnaires that provide
detailed information regarding family history, demo-
graphics, diet, physical activity, medications, smoking,
and alcohol intake. Systolic and diastolic blood pressures
were measured after subjects rest for at least 10 minutes,
and the average of the second and third measurements
was used as the subject’s blood pressure. Height, weight
and waist circumference were measured and BMI calcu-
lated as weight in kilograms divided by height in meters
squared.
Biochemical analyses
Venous blood samples were collected from subjects after
10 hour fasting. Plasma glucose, total cholesterol, triglyc-
erides and high density lipoprotein cholesterol (HDL-C)
were measured in fresh samples, using standardized en-
zymatic procedures in a Hitachi 902 analyzer (Hitachi
LTD, Tokyo, Japan). Accuracy and precision of lipid
measurements in our laboratory are under periodic sur-
veillance by the Centers for Disease Control and Preven-
tion Service (Atlanta, GA). Low density lipoprotein
cholesterol (LDL-C) was estimated by using the De Long
et al. formula [14]. Total high sensitive C-reactive pro-
tein (hs-CRP) levels were determined by immunonephe-
lometry on a BN ProSpec nephelometer (Dade Behring,
Marburg Hesse, Germany). Inter-assay coefficient of
variation was less than 6% for nephelometric determina-
tions. Serum FFA were measured by an enzymatic-
colorimetric assay (Wako Diagnostics, Chuo-Ku Osaka
Japan) in a Hitachi 902 auto analyser, with intra and
inter-assay variation coefficients below 3%. Total serum
adiponectin was measured by Enzyme Linked Immuno-
sorbent Assay (ELISA) technique (R & D Systems
Quantikne Kit, Minneapolis, Minnesota, USA) with intra
and inter-assay variation coefficients lower than 10%. Plasma
insulin concentrations were determined by a radio-
immunoassay (Millipore; RIA Kit, Cat. No. HI-14 K, St.
Charles, Missouri, USA), the intra and inter-assay vari-
ation coefficients were 2.1% and 6.8%, respectively. Insu-
lin resistance was estimated using the homeostasis
model assessment (HOMA-IR = insulin [μIU/mL] X glu-
cose mmol/22.5) [15]. Percentiles for insulin resistance,
FFA and adiponectin levels were established in a sub-
sample of the GEA control group (127 men and 169
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glucose ≥ 126 mg/dL, prior medical diagnosis, or anti-
diabetic treatment use) [16], and without cardiometabolic
risk factors, namely BMI < 30 kg/m2, blood pressure <
140/90 mmHg, fasting glucose < 100 mg/dL, HDL-C >
40 mg/dL in men and > 50 mg/dL in women, and trigly-
ceride levels < 150 mg/dL. Insulin resistance and high FFA
levels were defined as HOMA-IR and FFA levels ≥ 75th
percentile (HOMA-IR: >3.58 in women and >3.12 in men;
FFA levels: >0.745 mEq/L in women and >0.60 mEq/L
in men), while low ADIPO was defined as serum adipo-
nectin levels ≤ 25th percentile (≤8.67 μg/mL in women
and ≤5.30 μg/mL in men).
Computerized axial tomography study
Abdominal subcutaneous and visceral fat were quantified
by computed tomography in a tomographic abdomen slice
at the L4-L5 inter vertebral space. Computed tomography
was performed using a 64-channel multi-detector helical
computed tomography system (Somatom Sensation,
Siemens. Forciem, Bavaria, Germany) and interpreted by
experienced radiologists as described by Kvist et al. [17].
Elevated AVF was defined as AVF ≥ 75th percentile
(127 cm2 in women; 152.7 cm2 in men). This cut-off point
was also estimated in the sub-group of GEA participants
without cardiometabolic risk factors.
Statistical analysis
Data are presented as mean ± SD, median (interquartile
range), or prevalence for categorical variables. Compari-
sons were made by t test, ANOVA and Sheffe as Post
hoc, U Mann–Whitney, Kruskal-Wallis or Chi-squared
test, as appropriate. In order to explore whether low
ADIPO levels affect the AVF-IR association, the study
population was stratified in four groups as follows: 1)
Reference group: AVF < p75 (normal AVF) and adipo-
nectin > p25 (normal ADIPO), 2) subjects with normal
AVF and low ADIPO, 3)subjects with high AVF and nor-
mal ADIPO, and 4) subjects with high AVF and low
ADIPO levels. To study the effect of the FFA levels on
this association, the following groups were compared: 1)
Reference group: normal AVF and FFA < p75 (normal
FFA), 2) subjects with normal AVF and high FFA, 3)
subjects with high AVF and normal FFA, and 4) subjects
with high AVF and high FFA. Logistic regression models
were used to analyse the effect of low ADIPO and high
FFA levels on the association of high AVF with insulin
resistance. Age, BMI, hs-CRP, triglycerides, HDL-C, glu-
cose, total caloric intake, and total physical activity, were
included as co-variables. The interaction of ADIPO and
FFA levels with AVF was evaluated by including the
AVF*FFAs or AVF*ADIPO interaction terms in the lo-
gistic regression models [18]. All p values <0.05 were
considered as statistically significant. The analyses werecarried out with the statistical software SPSS v15.0 (SPSS
Chicago, II).
Results
The present study included 1217 GEA control subjects
(50.5% women), with a mean age of 52.5 ± 9.0 years,
BMI of 28.3 ± 4.3 Kg/m2, and HOMA-IR median of 3.7
(2.6-5.3). Women had higher subcutaneous abdominal
fat volume [320 (256–396) cm2 vs. 243 (183–307) cm2;
p < 0.0001] and lower AVF volume than men [124 (93–
166) cm2 vs. 168 (129–217) cm2; p < 0.0001]. Women
also had higher FFA [0.61 (0.49-0.76) mEq/L vs. 0.49
(0.39-0.61) mEq/L; p < 0.0001] and higher adiponectin
levels as compared to men [10.4 (6.7-15.7) μg/mL vs. 6.2
(4.0-9.4) μg/mL; p < 0.0001].
Table 1 shows the clinical characteristics of the study
population stratified according to gender, normal and
high AVF, and normal and low ADIPO levels. The preva-
lence of low ADIPO levels in individuals with normal
AVF was 28.2% in women and 32.9% in men, and this
prevalence was significantly higher in individuals with
high AVF (40.9% in women and 44.7% in men). Normal
AVF/low ADIPO individuals had significantly higher
BMI and triglyceride levelsas well as lower HDL-C levels
(in both genders), and significantly higher diastolic blood
pressure and glucose levels (only in men) as compared
to the reference group (p < 0.05). High AVF was associ-
ated with a less favorable metabolic profile in both gen-
ders, and high AVF/low ADIPO individuals showed the
lowest HDL-C and the highest triglyceride concentra-
tions among all study groups. Similarly, on stratifying ac-
cording to AVF and FFA levels, high AVF/high FFA
individuals showed the most unfavorable metabolic pro-
file (data not shown), although only increased systolic
blood pressure was statistically significant on compari-
son with the high AVF/normal FFA group, [women: 116
(108–130) mmHg vs. 111 (103–123) mmHg, p < 0.05;
men: 123 (115–131) mmHg vs. 118 (111–129) mmHg,
p < 0.05].
In women, high AVF, low ADIPO and high FFA were
all significantly associated with a higher prevalence of IR
(Figure 1). Moreover, high AVF/low ADIPO and high
AVF/high FFA combinations showed a stronger associ-
ation with IR than any of these parameters assessed in-
dividually. In contrast, the prevalence of IR in men with
high AVF was not significantly affected by low ADIPO
or high FFA levels as assessed by univariate analysis
(Figure 1), although logistic regression analyses adjust-
ing for confounding factors, revealed that low ADIPO,
but not high FFA, significantly increases the risk of IR
in men with high AVF (Figure 1 and Table 2). More-
over, normal AVF/low ADIPO and high AVF/normal
ADIPO women had a 3 fold increased risk of IR even
after controlling for FFA levels and other confounding
Table 1 Clinical characteristics of study subjects stratified by sex, abdominal visceral fat, and adiponectin
Normal AVF High AVF
Normal ADIPO Low ADIPO Normal ADIPO Low ADIPO
WOMEN
N 211 83 189 131
Age (years) 51 ± 9 49 ± 9 56 ± 8*† 52 ± 8†‡
BMI (kg/m2) 25(23 – 28) 26(24–29)* 30(27 – 33)*† 31(28–34)*†
SBP (mmHg) 106(97–118) 103(99–111) 113(105–124)*† 111(105–123)*†
DBP (mmHg) 67(62 – 73) 66(60–71) 71(66 – 76)*† 70(65–76)*†
LDL-C (mmol/L) 2.98 ± 0.75 3.13 ± 0.98 3.16 ± 0.83 2.98 ± 0.83
HDL-C (mmol/L) 1.47 ± 0.36 1.27 ± 0.34* 1.32 ± 0.36* 1.14 ± 0.31*‡
TG (mmol/L) 1.25(0.95–1.6) 1.59(1.2–2.1)* 1.65(1.3 – 2.2)* 1.76(1.4–2.3)*
Glucose (mmol/L) 4.66(4.4–4.9) 4.77(4.5–5.1) 5.05(4.7 – 5.3)*† 5.05(4.7–5.4)*†
HOMA-IR 2.5(2.0–3.4) 3.6(2.4–4.7)* 4.3(3.2 – 5.9)*† 5.0(3.9–6.9) *†‡
hs-CRP (nmol/L) 10.5(5.7–21.9) 12.4(6.7–31.4) 23.8(12.4 – 39.0)*† 28.6(12.4–45.7)*†
MEN
N 157 77 204 165
Age (years) 51 ± 11 48 ± 9 55 ± 10*† 52 ± 8†
BMI (kg/m2) 25(23–27) 26(25–29)* 29(27 – 32)*† 29(27–32)*†
SBP (mmHg) 112(106–119) 115(107–124) 121(111–133)*† 119(112–127)*†
DBP (mmHg) 69(65–75) 72(68–76)* 75(70 – 82)*† 75(70–81)*†
LDL-C (mmol/L) 2.98 ± 0.70 3.03 ± 0.75 3.19 ± 0.85 3.16 ± 0.93
HDL-C (mmol/L) 1.19 ± 0.28 1.04 ± 0.28* 1.06 ± 0.26* 0.98 ± 0.23*‡
TG (mmol/L) 1.34(0.97–2.0) 1.68(1.2–2.5)* 1.90(1.5 – 2.6)*† 2.07(1.56–3.01)*†‡
Glucose (mmol/L) 4.83(4.7–5.2) 5.05(4.7–5.3)* 5.05(4.7 – 5.4)* 5.16(4.9–5.4)*†
HOMA-IR 2.5(1.9–3.3) 3.2(2.2–4.8)* 4.3(3.0 – 5.7)*† 5.1(3.4–6.7) *†‡
hs-CRP (nmol/L) 8.6(4.8 – 16.2) 9.5(5.7 – 18.1) 13.3(7.6 – 25.7)*† 15.2(8.6–28.6)*†
Mean ± SD or median (interquartil range); ANOVA or Kruskal-Wallis. *p < 0.05 vs. normal AVF/ normal ADIPO; †p < 0.05 vs. normal AVF/low ADIPO; ‡p < 0.05 vs. high
AVF/normal ADIPO. AVF = Abdominal visceral fat; ADIPO = Adiponectin; BMI = Body mass index; SBP = Systolic blood pressure; DBP = Diastolic blood pressure;
LDL-C = Low density lipoprotein cholesterol cholesterol; HDL-C = High density lipoprotein cholesterol; TG = Triglycerides; hs-CRP = High sensitivity C-reactive protein.
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high AVF/low ADIPO group. Irrespective of the AVF,
the effect of low ADIPO on IR was higher than that ob-
served for high FFA levels. Because interactions terms
AVF*ADIPO or AVF*FFA were not statistically signifi-
cant in the logistic regression models, the results sug-
gest an additive and independent effect of AVF, ADIPO
and FFA levels on the prevalence of IR.
Discussion
This study shows for the first time that irrespective of
AVF, low ADIPO and high FFA levels are associated with
IR, and that the effect of low ADIPO is stronger than
that of high FFA levels. Moreover, an additive effect of
low ADIPO and high FFAs with high AVF on IR preva-
lence was observed. While subjects with high AVF or
low ADIPO had a three-fold increased risk of IR, the
combination of low ADIPO with high AVF doubled this
probability. Interestingly, high FFA levels were associatedwith IR only in females, but were significantly associated
with IR in both genders when combined with high AVF.
Our results suggest that high AVF, high FFA and low
ADIPO levels have an additive and independent effect
increasing the risk of IR. This is particularly relevant be-
cause insulin resistance is a common alteration among
obese subjects, and that both abnormalities are precur-
sors of T2DM and CAD.
Adiponectin is a constitutively secreted adipocyte pro-
tein. In obese individuals, ADIPO serum levels are fre-
quently low and show an inverse correlation with AVF,
but not with BMI or subcutaneous fat deposits [19,20].
It has been suggested that this protein is a potent
insulin-sensitizing agent [9,21]. Aguilar-Salinas et al. [22]
reported that obese subjects with high ADIPO levels had
lower insulin concentrations and a better metabolic pro-
file, as compared to obese subjects with low ADIPO levels.
Our results extend those observations, by suggesting that
low ADIPO levels are associated with a higher risk of IR,
Figure 1 Effect of adiponectin (ADIPO) and free fatty acids (FFA) levels on the prevalence of insulin resistance (HOMA-IR ≥ p75).
Subjects were stratified by normal or high abdominal visceral fat. *p < 0.05 as compared to normal AVF/normal ADIPO; †p < 0.05 as compared to
normal AVF/low ADIPO; ‡p < 0.05 as compared to high AVF/normal ADIPO, Chi-square test. Cut-off values are defined in material methods section.
Table 2 Regression logistic models* analyzing the effect of AVF, adiponectin and FFA on insulin resistance prevalence
Normal AVF High AVF
Normal ADIPO Low ADIPO Normal ADIPO Low ADIPO Interaction p
Women 1 3.7(2.1-6.6) 3.4(2.0-5.7) 7.6(4.2-13.8) 0.6
Men 1 1.9(1.0-3.6) 2.5(1.4-4.3) 4.1(2.6-7.2) 0.7
Normal AVF High AVF
Normal FFA High FFA Normal FFA High FFA
Women 1 2.2(1.1-4.1) 2.8(1.7-4.6) 4.5(2.3-8.8) 0.5
Men 1 0.8(0.4-1.8) 2.1(1.3-3.4) 2.3(1.2-4.2) 0.6
*Age, body mass index, high sensitive C-reactive protein, physical activity, total caloric intake, and FFA or adiponectin levels were included as co-variables
(similar results were obtained after including triglycerides, HDL-C and glucose plasma levels in the model). AVF = Abdominal visceral fat; FFA = Free fatty acids;
ADIPO = Adiponectin; HDL-C = High density lipoprotein cholesterol. Cut-off values are defined in material method section.
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Moreover, we found that the high AVF/low ADIPO com-
bination has a synergic effect on IR risk. These findings
are supported by in vitro and in vivo studies showing that
the interaction of adiponectin with its cellular receptors
(AdipoR1 and AdipoR2) activates AMP kinase promoting
the translocation of GLUT4 transporters, simultaneously
reduces hepatic glucose production by inhibiting the en-
zyme phosphoenolpyruvate carboxylase, inhibits the syn-
thesis of fatty acids and stimulates their oxidation [21].
Adiponectin also acts as an agonist of peroxisome prolif-
erator activated receptor (PPAR) gamma, leading add-
itional uptake of plasma glucose [21], and enhances
insulin sensitivity by increasing hepatic insulin receptor
substrate 2 (IRS-2). It has been also proposed that high-
molecular adiponectin binds to membrane T-cadherin of
adipocytes, forming intercellular spacers and increasing
the metabolic activity and insulin sensitivity of these cells
[23]. Thus, all these functions confer to adponectin a key
role as an insulin sensitizer in muscle, liver, and adipose
tissue [21,23].
Several studies have shown that FFA levels are fre-
quently high in obese individuals [10,11]. Excessive FFA
release by AVF is particularly deleterious because it ex-
poses the liver to increased FFA levels via portal circula-
tion, impairing insulin liver metabolism and promoting
IR [24]. However, studies analyzing the role of FFA on
the association of AVF with IR are scarce. While Milleret
al. [12] reported that FFAs do not participate in this as-
sociation, our results show that women with high AVF/
high FFA levels have a twofold increased risk of IR than
that of women with high AVF/normal FFA levels
(Table 2). The lack of association in men could be ex-
plained by the lower FFA levels observed in this gender,
and because several lines of evidence show that women
are more susceptible to the unfavorable metabolic effects
of obesity [25]. Of note, Miller et al. included both men
and women in his analyses, and did not analyse genders
separately. Thus, gender differences may explain the dis-
crepancies between both studies. Our results are sup-
ported by experimental studies showing a liver lipotoxic
effect of high FFA [11]. High FFA impair the insulin sig-
nalling pathway by decreasing GLUT4 transporter expres-
sion [26,27], and favouring ceramide and diacylglycerol
production [28].
No previous study has simultaneously analyzed the ef-
fect of low ADIPO and high FFA levels on the high
AVF-IR association. The results of the present study
suggest that both low ADIPO and high FFA play a role
in this through independent pathways and related mech-
anisms. These results are supported by a previous study
showing an association of adiponectin with IR, regard-
less of the circulating FFA [29]. Moreover, our data ex-
tend this information by showing that the effect of lowADIPO on IR is independent of AVF, and that its effect
on IR is stronger than that observed for high FFA. Al-
though these associations need to be confirmed in fur-
ther studies, it is important to point out that low
adiponectin concentrations, alone or combined with
high AVF, could be considered a major biomarker of IR.
Strengths and limitations
This study has several strengths. Firstly, the distribution
of body fat was measured by computed tomography,
which is a specific and reliable method to quantify AVF.
It was thus possible to assess the role of high AVF on
low ADIPO, high FFA and IR, above and beyond clinical
anthropometry. Secondly, the sample size of the study
population was large enough and both sexes were in-
cluded; which is important because female gender has
been shown to be more susceptible to unfavorable meta-
bolic effects of obesity. Third, multivariable analyses in-
cluded physical activity and caloric intake, known to
affect ADIPO, FFA levels, AVF and IR. Among the study
limitations, it should be mentioned that because this is
across-sectional design we cannot infer causality from
the results. Moreover, only total adiponectin was mea-
sured, and not its multimeric forms which are critical
determinants of IR. Nevertheless, because circulating
levels of high molecular adiponectin have been reported
to show a strong correlation with total adiponectin cir-
culating levels (r = 0.95, p < 0.0001) [30], the associations
observed here would be expected to be similar. Insulin
resistance was estimated by the HOMA-IR. This algo-
rithm is as surrogate marker of IR, more feasible for large
population studies, which correlate with the euglycemic
CLAMP, the gold standard for assessing IR [31]. Finally, it
should be noted that since there are no population-
specific thresholds for HOMA-IR, adiponectin, and AVF,
we used specific cut-off values obtained in our Mexican-
Mestizo population, as Bonora et al. [32] and The
European Group for the study of Insulin Resistance
have recommended [33]. Because differences in metabolic
markers measurements are well documented among dif-
ferent ethnic groups [34,35], these cut-off values cannot be
applied to other population. Using population specific cut-
off values may contribute to partly explain discrepancies in
associations among different studies and populations.
Conclusions
The results of the present study provide novel and import-
ant information about the combined effect of high AVF
and low ADIPO levels on the prevalence of IR. Further-
more, our data suggest that the effect of adiponectin on
the high AVF-IR association is stronger than the effect of
high FFA levels. Therefore, adiponectin could be used as
biomarker to identify subjects at high risk forT2DM and
CAD.
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